vs

Side-by-side financial comparison of FTAI Infrastructure Inc. (FIP) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $188.4M, roughly 1.7× FTAI Infrastructure Inc.). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -79.7%, a 61.5% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 95.9%).

FTAI Infrastructure Inc. owns, operates and invests in high-quality critical infrastructure assets across core sectors including transportation logistics, midstream energy, and power generation. It primarily serves North American markets, focusing on assets with stable long-term cash flows, contracted revenue streams, and strong market positions to deliver sustainable returns for stakeholders.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FIP vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.7× larger
MDGL
$321.1M
$188.4M
FIP
Growing faster (revenue YoY)
MDGL
MDGL
+114.9% gap
MDGL
210.8%
95.9%
FIP
Higher net margin
MDGL
MDGL
61.5% more per $
MDGL
-18.2%
-79.7%
FIP

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FIP
FIP
MDGL
MDGL
Revenue
$188.4M
$321.1M
Net Profit
$-150.2M
$-58.6M
Gross Margin
Operating Margin
-18.6%
Net Margin
-79.7%
-18.2%
Revenue YoY
95.9%
210.8%
Net Profit YoY
-387.6%
1.4%
EPS (diluted)
$-1.32
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FIP
FIP
MDGL
MDGL
Q1 26
$188.4M
Q4 25
$143.5M
$321.1M
Q3 25
$140.6M
$287.3M
Q2 25
$122.3M
$212.8M
Q1 25
$96.2M
$137.3M
Q4 24
$80.8M
$103.3M
Q3 24
$83.3M
$62.2M
Q2 24
$84.9M
Net Profit
FIP
FIP
MDGL
MDGL
Q1 26
$-150.2M
Q4 25
$-97.7M
$-58.6M
Q3 25
$-104.5M
$-114.2M
Q2 25
$-70.0M
$-42.3M
Q1 25
$120.2M
$-73.2M
Q4 24
$-124.7M
$-59.4M
Q3 24
$-43.0M
$-107.0M
Q2 24
$-48.1M
Gross Margin
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
96.7%
Q4 24
Q3 24
Q2 24
Operating Margin
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
-45.7%
-18.6%
Q3 25
-70.8%
-39.7%
Q2 25
-56.4%
-22.2%
Q1 25
81.8%
-57.8%
Q4 24
-152.7%
-64.8%
Q3 24
-51.7%
-187.1%
Q2 24
-56.4%
Net Margin
FIP
FIP
MDGL
MDGL
Q1 26
-79.7%
Q4 25
-68.1%
-18.2%
Q3 25
-74.4%
-39.8%
Q2 25
-57.2%
-19.9%
Q1 25
125.0%
-53.4%
Q4 24
-154.4%
-57.5%
Q3 24
-51.6%
-172.0%
Q2 24
-56.7%
EPS (diluted)
FIP
FIP
MDGL
MDGL
Q1 26
$-1.32
Q4 25
$-1.04
$-2.55
Q3 25
$-1.38
$-5.08
Q2 25
$-0.73
$-1.90
Q1 25
$0.89
$-3.32
Q4 24
$-1.21
$-2.50
Q3 24
$-0.45
$-4.92
Q2 24
$-0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FIP
FIP
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$37.9M
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$-122.5K
$602.7M
Total Assets
$5.7B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FIP
FIP
MDGL
MDGL
Q1 26
$37.9M
Q4 25
$57.4M
$198.7M
Q3 25
$34.7M
$295.7M
Q2 25
$33.6M
$186.2M
Q1 25
$26.3M
$183.6M
Q4 24
$27.8M
$100.0M
Q3 24
$20.3M
$232.7M
Q2 24
$33.1M
Total Debt
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
$3.8B
$339.9M
Q3 25
$3.7B
$339.8M
Q2 25
$3.1B
$118.4M
Q1 25
$2.8B
$118.0M
Q4 24
$1.6B
$117.6M
Q3 24
$1.5B
$117.1M
Q2 24
$1.6B
Stockholders' Equity
FIP
FIP
MDGL
MDGL
Q1 26
$-122.5K
Q4 25
$21.3M
$602.7M
Q3 25
$181.1M
$625.7M
Q2 25
$375.5M
$696.0M
Q1 25
$476.2M
$710.6M
Q4 24
$202.7M
$754.4M
Q3 24
$370.8M
$777.2M
Q2 24
$394.8M
Total Assets
FIP
FIP
MDGL
MDGL
Q1 26
$5.7B
Q4 25
$5.7B
$1.3B
Q3 25
$5.5B
$1.4B
Q2 25
$4.4B
$1.0B
Q1 25
$4.1B
$996.6M
Q4 24
$2.4B
$1.0B
Q3 24
$2.4B
$1.1B
Q2 24
$2.5B
Debt / Equity
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
176.99×
0.56×
Q3 25
20.59×
0.54×
Q2 25
8.21×
0.17×
Q1 25
5.79×
0.17×
Q4 24
7.84×
0.16×
Q3 24
4.14×
0.15×
Q2 24
3.94×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FIP
FIP
MDGL
MDGL
Operating Cash FlowLast quarter
$-69.4M
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FIP
FIP
MDGL
MDGL
Q1 26
$-69.4M
Q4 25
$-2.8M
$-133.5M
Q3 25
$-24.4M
$79.8M
Q2 25
$-5.2M
$-47.1M
Q1 25
$-85.7M
$-88.9M
Q4 24
$-8.1M
$-104.5M
Q3 24
$14.2M
$-67.0M
Q2 24
$-17.6M
Free Cash Flow
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
$-68.6M
$-133.8M
Q3 25
$-90.7M
$79.0M
Q2 25
$-87.5M
Q1 25
$-151.7M
Q4 24
$-34.3M
$-104.7M
Q3 24
$-11.7M
$-67.8M
Q2 24
$-32.1M
FCF Margin
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
-47.8%
-41.7%
Q3 25
-64.5%
27.5%
Q2 25
-71.6%
Q1 25
-157.7%
Q4 24
-42.4%
-101.3%
Q3 24
-14.0%
-109.0%
Q2 24
-37.9%
Capex Intensity
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
45.9%
0.1%
Q3 25
47.2%
0.3%
Q2 25
67.3%
0.0%
Q1 25
68.6%
0.0%
Q4 24
32.5%
0.2%
Q3 24
31.1%
1.3%
Q2 24
17.2%
Cash Conversion
FIP
FIP
MDGL
MDGL
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
-0.71×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FIP
FIP

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons